BDSX
Biodesix Inc

1,692
Mkt Cap
$155.27M
Volume
114,238.00
52W High
$19.13
52W Low
$3.44
PE Ratio
-3.33
BDSX Fundamentals
Price
$15.96
Prev Close
$15.75
Open
$15.68
50D MA
$9.63
Beta
0.50
Avg. Volume
136,529.04
EPS (Annual)
-$4.67
P/B
-52.73
Rev/Employee
$264,967.07
$105.11
Loading...
Loading...
News
all
press releases
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·4h ago
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·4h ago
News Placeholder
Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX
Monashee Investment Management LLC lowered its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 95.0% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·2d ago
News Placeholder
Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS
Biodesix (NASDAQ:BDSX - Get Free Report) released its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by...
MarketBeat·4d ago
News Placeholder
GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX
GSA Capital Partners LLP reduced its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The...
MarketBeat·4d ago
News Placeholder
Biodesix, Inc. Q4 Loss Drops
(RTTNews) - Biodesix, Inc. (BDSX) released Loss for fourth quarter of -$3.98 million...
Nasdaq News: Markets·5d ago
News Placeholder
Biodesix Q4 Earnings Call Highlights
Biodesix (NASDAQ:BDSX) reported fourth-quarter and full-year 2025 results that management said reflected progress on its priorities of accelerating revenue growth, improving operational leverage, and...
MarketBeat·5d ago
News Placeholder
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of +53.33% and +14.11%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Biodesix (NASDAQ:BDSX) CEO Scott Hutton Sells 1,490 Shares
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 1,490 shares of the firm's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $12.78...
MarketBeat·7d ago
News Placeholder
Insider Selling: Biodesix (NASDAQ:BDSX) CEO Sells 1,490 Shares of Stock
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 1,490 shares of the firm's stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price...
MarketBeat·8d ago
<
1
2
...
>

Latest BDSX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.